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Introduction
β-thymosins are a family of small peptides that were origi-
nally proposed to be thymic hormones.1 They were identified
as actin monomer binding proteins, controlling the availabili-
ty of actin for polymerization. They may, therefore, have a
crucial role in regulating cellular functions involving actin
polymerization/depolymerization cycles. Currently, 15 β-
thymosins have been identified and characterized as highly
conservative 5-kDa peptides containing 40 to 44 amino acid
residues. In most mammalian tissues, thymosin-β 4 (Tβ4), the
most abundant thymosin peptide, Tβ10 and Tβ15, have been
studied as important members of the β-thymosin family.2
Several studies reported that these genes are over-expressed
in solid tumors, which could be correlated to the angiogenic
and metastatic potential of the studied tumors.3
Multiple myeloma (MM) is a hematologic malignancy char-
acterized by the accumulation of monoclonal plasma cells
(PC) in the bone marrow (BM). MM cell biology can be dis-
sected into the interactions of MM cells with their surround-
ing stroma (matrix proteins, cytokines and BM cells) and in
the acquisition of essential changes in cell behavior, such as
self-sufficiency in growth signals, evasion of apoptosis and
acquisition of invasive and spreading capacities.4 Earlier
reports indicated that Tβ4 was down-regulated in RNA from
primary human MM cells and cell lines.5
This observation is in contrast to the results obtained in
most solid tumors where an upregulation is seen in malignant
cells compared to their normal counterparts. Cha et al.
showed that overexpression of Tβ4 resulted in an increased
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Thymosin β4 (Tβ4) is a polypeptide involved in cellular
proliferation, differentiation, and migration, over-
expressed in several tumor entities. We evaluated its
expression and function in 298 newly diagnosed multiple
myeloma patients and the murine 5TMM model. Mean
Tβ4 expression was significantly lower in myeloma cells
compared to normal plasma cells (P<0.001). The same
observation can be made in the 5TMM-mouse model by
qRT-PCR and ELISA. Here, Tβ4 overexpression by lentivi-
ral transduction of 5T33MMvt-cells led to significantly
decreased proliferative and migratory capacities and
increased sensitivity to apoptosis-induction. Mice injected
with Tβ4 over-expressing myeloma cells showed a longer
survival compared to mice injected with controls (88,9 vs.
65,9 days, P<0.05). In 209 MM patients treated with high-
dose therapy and autologous stem cell transplantation,
expression of Tβ4 below the median was associated with
a significantly shorter event free survival (37.6 vs. 26.2
months, P<0.05). In conclusion, our results indicate a pos-
sible tumor suppressive function of Tβ4.
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ABSTRACT
metastatic capacity of lung cancer cells and increased
angiogenic response.6
Since migration, invasion and associated angiogenesis
are key features in MM biology, we were interested in
studying Tβ4 expression in a large panel of MM patients
and its functionality in the murine 5TMM model. 
Design and Methods
Gene expression analysis on human myeloma cells
Tβ4 expression was analyzed in purified PCs from BM samples
obtained from 14 healthy donors, 11 patients with monoclonal gam-
mopathy of unknown significance (MGUS) and 298 previously
untreated multiple MM patients at the University Hospitals of
Heidelberg or Montpellier.7 Of these, 209 MM patients were treated
by high-dose therapy and autologous stem cell transplantation
(ASCT). Biotinylated complementary RNA (cRNA) was amplified
according to the Affymetrix labeling protocol (Affymetrix, Santa
Clara, CA, USA). cRNA from a first group of patients (7 normal
donors, 7 MGUS and 65 MM patients) was hybridized to the human
U133 A and B. This group will be referred to as the HM1-group. A
second independent validation group of patients (7 normal donors, 16
MGUS and 233 MM patients) was named the HM2 group. For these
patients, the U133 2.0 GeneChip was used. These micro-array data
had been previously used for several analyses, but thymosin β4
expression had never been analyzed before.8,9 HM2 data were cor-
rected for batch effect due to the usage of different labeling kits
according to Johnson et al.10 Expression data were gcrma-normalized
and analyzed by the bioconductor packages for R. For patients’ char-
acteristic see Online Supplementary Table S1.
The 5T2MM and 5T33MM murine models 
of myeloma
The 5TMM models originated in elderly C57Bl/KaLwRij mice.11
The 5T33MMvivo (5T33MMvv) cells grow in vitro stroma-dependent-
ly with a limited survival while the 5T33MMvitro (5T33MMvt) cell
line is a clonally identical variant that originated from an in vitro cul-
ture of 5T33MMvv cells, growing BM stroma-independently in
RPMI-1640 supplemented with 10% bovine serum 1% natriumpyru-
vate, 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glu-
tamine (all from Biowhittaker, Verviers, Belgium).12
Quantification of intracellular protein levels of Tβ4 and
F-Actin G-Actin
Enzyme-Linked Immunosorbent Assays (ELISA) for measuring
Tβ4 concentrations were performed according to the manufacturer’s
instructions (Immundiagnostik, Bensheim, Germany). Cells (107)
were lyzed in a phosphate buffer containing 0.14 M NaCl, 2.6 M KCl,
8 mM Na2HPO4, 1.4 M KH2PO4 and 1% Triton X100 and sonicat-
ed with an ultrasound finger. Protein levels and ratios between F-
Actin and G-Actin were determined using the G-actin/F-actin in vivo
assay kit (Cytoskeleton Inc, Denver, USA).
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed using the
ABI Prism 7700 Sequence Detection System. For the detection of
both human and mouse Tβ4 mRNA and the endogenous reference
gene GUS, Assays on Demand (Applied Biosystems) were used. To
verify the results obtained with the microarrays studies, Tβ4 expres-
sion was measured in 3 cell lines and in 3 patient samples and their
correlations statistically verified using a Spearman correlation test.
Generation of 5T33MMvt cells over-expressing Tβ4
A lentiviral transferplasmid encoding mouse Tβ4 (m Tβ4) was con-
structed. The mTβ4 gene was obtained from HJ Cha (NIDCR, NIH,
Bethesda, USA)6 and inserted into the transferplasmid pHR'tripCMV-
IRES-tNGFR-SIN.13 mTβ4-encoding lentiviral vector particles were
produced in 293T cells, collected, ultracentrifugated and their viral
titer determined.14 After transduction, 5T33MMvt cells were surface
stained using an in-house biotinylated anti-tNGFR antibody and puri-
fied by FACS sorting into a 6-well plate (Becton Dickinson,
FACSVantage). Next, they were analyzed for Tβ4 expression by RT-
PCR. The 5T33MMvt cells over-expressing Tβ4 will be referred to as
5T33MMvtTβ4+.
In vitro and in vivo effects of Tβ4 overexpression
In vitro proliferation was assessed by measuring DNA synthesis
using a 3H-thymidine incorporation assay, as described earlier.15
Apoptosis sensitivity of the MM cells was analyzed by staining with
FITC labeled-annexin V and propidium iodide according to the man-
ufacturers’ instructions (BD Biosciences, Erembodegem, Belgium). In
vitro migration studies were performed using Transwell chambers and
10% fetal calf serum as chemoattractant and were quantified through
flow cytometry. To determine the effect of Tβ4 overexpression on
survival, groups of 10 C57BLKaLwRij mice were intravenously inject-
ed with either 5×105 5T33MMvtTβ4+ or wild-type 5T33MMvt cells.
Animals were sacrificed when they showed signs of morbidity,
namely hind limb paralysis. Kaplan-Meier analysis was used to deter-
mine a difference in the survival.
Results and Discussion
Different studies indicated a pivotal role of Tβ4 in the
metastatic process of solid tumors.16,17 An adenoviral-
based overexpression of Tβ4 was applied in a colon cancer
and melanoma model showing increased growth, motility
and invasive capacities in vitro and a larger tumor load in
vivo.18,19 Since proliferation, migration and invasion are part
of the hallmarks of the biology of MM, we were interest-
ed in investigating an involvement of Tβ4 in this disease.
We first investigated the Tβ4 expression pattern in 298 pri-
mary MM-cell samples and 14 normal plasma cell samples
from healthy donors. Tβ4 expression is significantly lower
in MM cells of the HM1 group (P<0.05) and HM2 group
(P<0.001) compared to normal plasma cells. This holds
true for a significantly lower Tβ4 expression in its pre-
malignant stage (MGUS), its early (Durie Salmon stage I)
or late stage (Durie Salmon II and III) in both HM1 and
HM2 groups (P<0.001) (Figure 1A). No relevant correla-
tion could be found between Tβ4 expression and percent-
age of plasma cell infiltration in the bone marrow smear.
Gene expression assessed by DNA-microarray correlates
well with qRT-PCR performed on MM patient samples
(coefficient of correlation r=0.993, P<0.001). These data
are in agreement with results from Gondo et al. showing a
decrease in Tβ4 expression in a small number of MM sam-
ples by Northern blot analysis.5
Given the differential Tβ4 expression in MM patients,
we subsequently investigated a possible prognostic value
and influence on event free (EFS) and overall survival (OS)
in our patient population. As Tβ4 was expressed in all MM
cells, we examined the survival of 209 patients by compar-
ing patients with Tβ4 expression above (Tβ4high) and below
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(Tβ4low) the median (Figure 1B). Patients with Tβ4high com-
pared with Tβ4low show a significantly longer median EFS
(n=209, 37.6 months vs. 26,2, P<0.05), but only a trend
regarding OS (P=0.1). Concerning EFS, multivariate analy-
ses on Tβ4 expression with either ISS or β2-microglobulin
indicated an independent (P=0.04) prognostic value of Tβ4
expression regarding ISS (P<0.001), but not (P=0.07)
regarding β2-microglobulin (P=0.003) levels. In multi-vari-
ate analyses for OS, ISS and β2-microglobulin appear as
significant (P=<0.001) variables, whereas Tβ4 expression
fails to reach independence (P=0.09 and P=0.01, respec-
tively).
A supervized analysis of expression data comparing the
Tβ4high to the Tβ4low group identified over 300 significantly
differentially expressed genes. These genes are listed in
Online Supplementary Table S2. Analysis of their biological
function allowed them to be divided into main functional
categories and this distribution is illustrated in Figure 1C.
Signal transduction, protein metabolism and nuclear func-
tions were the largest categories, but 19 genes were impli-
cated in cytoskeletal organization, and 32 genes in lym-
phoid differentiation and immunoglobulin processing. In
general, these gene clusters indicate a biological difference
between MM cells of the two patient groups. 
The data obtained in MM patients were also seen in the
5T33MM murine MM model by qRT-PCR demonstrating
a decreased mRNA expression in 5TMM cells compared
to normal BM cells (P<0.001, Figure 1D). Competitive
ELISA confirmed these results on protein level (results not
shown). To study functional effects of Tβ4, the gene was
over-expressed using a lentiviral expression vector. The
5T33MMvt cell line was stably transduced and after sub-
cloning, a 99% pure clone with strong t-NGFR expression
was obtained. qRT-PCR confirmed the overexpression of
Tβ4 compared to control cells (Figure 2A).
To assess the functional involvement of differential Tβ4
expression we used the 5T33MMvt and 5T33MMvtTβ4+
cell lines. In a 3H thymidine assay, 5T33MMvtTβ4+ cells
showed a significant decrease in DNA synthesis compared
to control cells (P<0.05). 5T33MMvtTβ4+ cells showed a sig-
nificantly increased sensitivity to vinca-alkaloids (vin-
blastin) and bortezomib (Figure 2B; P<0.001 for both
bortezomib and vinblastin). 
Likewise, bortezomib induced apoptosis was higher in
5T33MMvtTβ4+ compared with 5T33MMvt cells (P<0.05;
Figure 2C). In addition to affect survival pathways, Tβ4
overexpression reduced migratory capacities of 5T3MM
cells; the percentages of cells that migrated in basal condi-
tions and in 10%FCI was significantly lower in
5T33MMvtTβ4+ compared to control cells (P<0.05; Figure
2D). The relative increase after stimulation (compared to
basal conditions) was, however, similar in both popula-
tions. We further examined the effects of Tβ4 expression
on tumor development and survival of diseased mice by
injecting mice intravenously with 5T33MMvtTβ4+ or con-
trol cells. In this study, the mean survival of mice injected
with control cells was significantly shorter 65.9 days (SD
6.6 days), compared to 88.9 days (SD 9.3 days) for mice
injected with 5T33MMvtTβ4+ cells (P<0.05; Figure 2F).
These in vivo results confirm data obtained using the in
vitro proliferation and apoptosis assays. 
In solid tumors, Tβ4 expression is frequently upregulat-
ed in malignant and metastatic cells. In these cancers,
higher Tβ4 expression resulted in increased metastatic and
invasive capacities of tumor cells, while proliferation
remained unaffected.6 In hematologic disorders, malignant
plasma cell disorders, such as plasma cell leukemia and
MM were the rare disorders that showed a decreased Tβ4
expression.5,20 In contrast to solid tumors, publications on
the function of Tβ4 in hematologic conditions are scanty
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Figure 1. (A) The micro-array data
obtained for the Tβ4 expression
in CD138+ sorted BM plasma
cells from healthy donors and
MM patients. These results were
validated by quantitative RT-PCR.
MGUS: monoclonal gammopathy
of undetermined significance,
MM multiple MM, SD: Salmon
and Durie Stage. (B) The event
free survival of Tβ4high and Tβ4low
patients. Patients with Tβ4low MM
had statistically significantly
decreased event free survivals
compared to patients with Tβ4high
MM (P<0.001), while also their
overall survival tended to be
shorter. (C) The differently
expressed genes between Tβ4high
and Tβ4low patient groups. After
identification of the gene, these
were grouped into similar biologi-
cal function. A complete list of
the genes can be found in Online
Supplementary Table S2. (D) A
similar gene expression pattern
was observed in the murine
5TMM models where Tβ4 mRNA
expression in 5T33MM and
5T2MM invaded BM was lowered
compared to normal BM cells. 
Micro-array data on Tβ4 expression
in a myeloma patient population
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but indicate some inhibitory activity. Tβ4 was initially iso-
lated and purified from a thymic protein preparation,
called thymosin fraction-5. Addition of this protein frac-
tion to different leukemic cell lines resulted in a decrease
in growth responses.21 Similar inhibitory effects were
recently described for Tβ4 on hematopoietic stem cells,22
bone marrow derived mast cells23 and human promyelo-
cytic leukemia cells,24 in agreement with the results pre-
sented here. Whereas a mechanistic explanation of this
discrepancy is beyond the scope of this paper, further
investigations are clearly merited.
Since Tβ4 has been shown to bind G-actin in a 1:1 man-
ner and thus affects the polymerization of G-Actin into F-
Actin, we analyzed in a semi-quantitative way, intracellu-
lar G-actin and F-Actin. This quantification showed a low-
ered G-Actin-F-Actin ratio after Tβ4 overexpression
(Figure 2E). F-Actin is of particular importance in
cytoskeleton changes involved in cellular migration and in
microtubuli organization controlling the mitotic spin-
dle.25,26 In line with these results, vinca-alkaloids (e.g. vin-
blastine used here) with micro-tubulin (polymerization)
inhibitory activity, had more affect on the proliferation
capacities of 5T33MMvtTβ4+ cells than on control cells
(Figure 2B). Since immunohistochemical studies also
showed a nuclear staining of Tβ4 in 5TMM cells (results not
shown), involvement of other pathways might also be
implicated. Supervized gene analysis comparing Tβ4high
with Tβ4low found different groups of genes differently
expressed, including genes involved in cytoskeleton
organization, nuclear homeostasis, lymphocyte differenti-
ation and protein metabolism, which might indicate that
the role of Tβ4 is more complicated than initially sup-
posed.
In conclusion, our results propose a tumor suppressive
function of Tβ4 expression in MM with impact on survival.
Tβ4 was down-regulated in MM cells of patients compared
to the normal BM plasma cells and studies with the murine
5T33MM model show a decreased in vitro and in vivo tumor
growth for cells over-expressing the Tβ4 gene. 
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Figure 2. (A) Schematic representation of the modified lentiviral transfer plasmid and results of RT-PCR and qRT-PCR indicating the pres-
ence of the inserted Tβ4 gene in cultured 5T33MMvtTβ4+ cells. (B) 3H thymidine uptake revealed a decreased DNA synthesis rate in
5T33MMvtTβ4+ cells compared to wild-type cells. Incubation with the anti-MM agent bortezomib (5 nM) or the micro-tubuli inhibitor vinblas-
tine (2,5 µM) had significantly (P<0.001) stronger effects on 5T33MMvtTβ4+ cells than on control cells. A similar observation was made in
apoptosis studies (C), where 5nM of bortezomib resulted in a significantly (P<0.05) increased apoptotic cell population after 18h incuba-
tion. (D) The effects of Tβ4 overexpression on migration of 5T33MMvt cells: using 10% fetal calf serum as chemo-attractant, only 10.8%
(SD 6.6%) of 5T33MMvtTβ4+ cells migrated compared to 34.7% (SD 15.9%) of the control 5T33MMvt cells (P<0.05). (E) (Upper) The F-actin
and G-actin bands of 5T33MMvt and 5T33MMvtTβ4+ cells. The graph illustrates the ratios of quantified F-actin and G-actin. In 5T33MMt cells
actin is present in its polymerized form, whereas Tβ4 overexpression results in decreased F-actin formation and a greater pool of G-actin.
(F) C57Bl/KaLwRij mice were injected with 5T33MMvt wild-type and 5T33MMvtTβ4+ cells. Kaplan-Meier analysis showed a significantly dif-
ferent survival between these 2 groups with a mean survival of mice injected with 5T33MMvt wild type of 65.9 days (SD 6.6 days), com-
pared to 88.9 days (SD 9.3 days) for mice injected with 5T33MMvtTβ4+ cells. (P<0.05). LTR: long terminal repeat; gag: frame-shifted gag
gene; RRE: rev-responsive element; CMV: cytomegalovirus promotor trip: central polypurine tract + termination sequence; Ires: internal ribo-
somal entry site; tNGFR: truncated form of the nerve growth factor receptor.
A lentiviral vector containing the Tβ4 sequence under
influence of a CMV promotor and t-NGFR reporter gene
Tβ4 overexpression reduces migratory capacities of
5T33MMvt cells
Tβ4 overexpression influences intracellular 
G-actin/F-actin ratios
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Tβ4 overexpression results in decreased proliferation
and increased sensibility to anti-myeloma agents
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